Диссертация (Фибрилляции предсердий - предикторы прогрессирования, эволюция клинического течения и выбор стратегии лечения), страница 38

[etal.]// J Hypertens. – 2009- Vol 27(2)- P.410-7.297. Sculpher M. Subgroups and Heterogeneity in Cost-EffectivenessAnalysis./ Sculpher M. // Pharmacoeconomics. -2008-Vol 26(9)- P.799–806.298. Sellers M.B. Atrial fibrillation, anticoagulation, fall risk, andoutcomes in elderly patients./ Sellers M.B. [et al.] // Am Heart J. – 2011- Vol161(2)- P.241-6.299. Shibata Y. Impairment of Pulmonary Function is an IndependentRisk Factor for Atrial Fibrillation: The Takahata Study.

/ Shibata Y. [et al.] // IntJ Med Sci - 2011- Vol 8(7)-P.514-22.300. Shimizu Y. Chronic kidneydisease and drinking status in relation torisks of stroke and its subtypes: the Circulatory Risk in Communities Study(CIRCS). / Shimizu Y. [et al.] //Stroke – 2011-Vol 42-P. 2531-7.255301. Shimony A. Usefulness of right ventricular dysfunction to predictnew-onset atrial fibrillation following coronary artery bypass grafting./ ShimonyA.

[et al.] //Am J Cardiol- 2014-Vol 113-P. 913–18.302. Shantsila E. Left ventricular fibrosis in atrial fibrillation. / ShantsilaE. [et al.] //Am J Cardiol.- 2013 – Vol 111(7)- P.996-1001303. Shroff SC. Selective aldosterone blockade suppresses atrialtachyarrhythmias in hear failure. / Shroff SC. [et al.]//J CardiovascElectrophysiol. - 2006 – Vol 17(5)- P.534-41.304. Shukla A.

Avoiding permanent atrial fibrillation: treatmentapproaches to prevent disease progression. / Shukla A. [et al.] //Vascular Healthand Risk Management. – 2014- Vol 10- P. 1–12.305. Singh JA. Allopurinol and the risk of atrial fibrillation in the elderly:a study using Medicare data. /Singh JA, Yu S. //Ann Rheum Dis -2017-Vol 76 P.

72–8.306. Sinner M. Genome-wide association studies: past, present, andfuture./ Sinner M. [et al.] // Cardiovasc Res.- 2011- Vol 89(4)-P.701–709.307. Sood S. Intracellular calcium leak due to FKBP12.6 deficiency inmice facilitates the inducibility of atrial fibrillation./ Sood S.

[et al.]// HeartRhythm.- 2008-Vol 5(7)-P.1047–1054.308. Stefansdottir H. Trends in the incidence and prevalence of atrialfibrillation in Iceland and future projections. / Stefansdottir H. [et al.]//Europace.- 2011- Vol 13(8)- P.1110-7.309. Stewart S. Population prevalence, incidence, and predictors of atrialfibrillation in the Renfrew/ Paisley study./ Stewart S. [et al.] // Heart – 2001- Vol86- P.516–521.310. Sullivan S.

D. Interventions for the treatment of atrial fibrillation: Asystematic literature review and meta-analysis/ Sullivan S. D. [et al.]Cardiol. -2012- Mar 31- P.345-49.// Int J256311. Swedberg K. Eplerenone and atrial fibrillation in mild systolic heartfailure: results from the EMPHASIS-HF (Eplerenone in Mild PatientsHospitalization And SurvIval Study in Heart Failure) study./ Swedberg K. [et al.]//J Am Coll Cardiol.

- 2012 – Vol 59(18)- P.1598-603.312. Tamariz L. Association of serum uric acid with incident atrialfibrillation (from the Atherosclerosis Risk in Communities [ARIC] study)./Tamariz L. [et al.] //Am J Cardiol – 2011- Vol 108- P.1272–6.313. Tamariz L. Association between serum uric acid and atrialfibrillation: a systematic review and meta-analysis. / Tamariz L.

[et al.] //HeartRhythm- 2014- Vol 11- P.1102–8.314. Tekin G. Serum uric acid levels are associated with atrial fibrillationin patients with ischemic heart failure./ Tekin G. [et al.] // Angiology 2013- Vol64- P.300–3.315. Tsagalis G. Renal dysfunction in acute stroke: an independentpredictor of long-term all combined vascular events and overall mortality./Tsagalis G. [et al.] //Nephrol Dial Transplant – 2009- Vol 24- P. 194-200.316. Tsagalis G. Atrial fibrillation in chronic hemodialysis patients:prevalence, types, predictors, and treatment practices in Greece./ Tsagalis G.

[etal.] // Artif Organs -2011- Vol 35- P. 916-22.317. Tsai CT. Increased expression of mineralocorticoid receptor inhuman atrial fibrillation and a cellular model of atrial fibrillation./ Tsai CT. [etal.] //J Am Coll Cardiol.- 2010 –Vol 55(8)- P.758-70.318. Tsai CT. Tachycardia of atrial myocytes induces collagen expressionin atrial fibroblasts through transforming growth factor beta-1. / Tsai CT. [et al.]//Cardiovasc Res. -2011- Vol 89(4)-P.805–815.319. Tveit A. Candesartan in the prevention of relapsing atrial fibrillation./ Tveit A.

[et al.]//Int J Cardiol -2007-Vol 120- P.85–91.320. Ueng KC. Use of enalapril to facilitate sinus rhythm maintenanceafter external cardioversion of long-standing persistent atrial fibrillation. Results257of a prospective and controlled study. / Ueng KC. [et al.] //Eur Heart J 2003-Vol24-P.2090–8.321. Umetani K. High prevalence of paroxysmal atrial fibrillation and/oratrial flutter in metabolic syndrome.

/ Umetani K. [et al.] // Circ J. -2007- Vol71(2)-P.252-5.322. Valbusa F. Relation of elevated serum uric acid levels to incidence ofatrial fibrillation in patients with type 2 diabetes mellitus. / Valbusa F. [et al.] //Am J Cardiol -2013-Vol 112- P.499–504.323. Van Den Berg MP. Effects of lisinopril in patients with heart failureand chronic atrial fibrillation. / Van Den Berg MP. [et al.]//J Card Fail- 1995-Vol11-P.355– 63.324. Van Gelder IC. Lenient versus strict rate control in patients withatrial fibrillation./ Van Gelder IC. [et al.]//N Engl J Med- 2010-Vol 362-P.1363–73.325. Van Gelder IC. A comparison of rate control and rhythm control inpatients with recurrent persistent atrial fibrillation.

/ Van Gelder IC. [et al.] //NEngl J Med – 2002- Vol 347-P.1834-1840.326. Van Oosten EM. Effect of preoperative obstructive sleep apnea onthe frequency of atrial fibrillation after coronary artery bypass grafting. / VanOosten EM. [et al.] //Am J Cardiol- 2014- Vol 113- P.919–23.327. Veasey RA.

The natural history of atrial fibrillation in patients withpermanent pacemakers: is atrial fibrillation a progressive disease?/ Veasey RA.[et al.] // J Interv Card Electrophysiol. – 2015- Jul 3-P.435-440.328. Verdecchia P. Atrial fibrillation in hypertension: predictors andoutcome./ Verdecchia P. [et al.] // Hypertension – 2003- Vol 41- P.218-223.329. Vermes E.

Enalapril decreases the incidence of atrial fibrillation inpatients with left ventricular dysfunction: insight from the Studies of LeftVentricular Dysfunction (SOLVD) trials. / Vermes E. [et al.]//Circulation 2003Vol 107-P.2926 –31.258330. VoigtN.CellularandMolecularMechanismsofAtrialArrhythmogenesis in Patients With Paroxysmal Atrial Fibrillation./ Voigt N. [etal.]//Circulation.- 2014-Vol 129(2)-P.145–156.331. Wachtell K. Angiotensin II receptor blockade reduces new-onsetatrial fibrillation and subsequent stroke compared to atenolol: the LosartanIntervention for End Point Reduction in Hypertension (LIFE) study./ Wachtell K.[et al.] // J Am Coll Cardiol -2005-Vol 45- P. 712–9.332. Wakili R. Recent advances in the molecular pathophysiology ofatrial fibrillation./ Wakili R.

[et al.] // The Journal of Clinical Investigation. 2011- Vol 121(8)- P. 2955–2968.333. Wang TJ. Temporal relations of atrial fibrillation and congestiveheart failure and their joint influence on mortality: the Framingham Heart Study. /Wang TJ. [et al.] //Circulation. - 2003 - 107(23)- P.2920-5.334. Wang Z. MicroRNAs and atrial fibrillation: new fundamentals./Wang Z. [et al.] // Cardiovasc Res.

– 2011 – Vol 89(4)-P.710–721.335. Watanabe H. Close bidirectional relationship between chronic kidneydisease and atrial fibrillation: the Niigata preventive medicine study. / WatanabeH. [et al.] // Am Heart J- 2009-Vol 158(4)- P.629–36.336.

Weckbach, L.T. MicroRNAs as a diagnostic tool for heart failure andatrial fibrillation./ Weckbach, L.T. [et al.] // Curr Opin Pharmacol. – 2016-Vol27-P.24–30.337. Wijffels MC. Atrial fibrillation begets atrial fibrillation. A study inawake chronically instrumented goats./ Wijffels MC.

[et al.] // Circulation -1995Vol 92- P.1954–68.338. Wolf PA. Atrial fibrillation as an independent risk factor for stroke:the Framingham Study. / Wolf PA. [et al.] // Stroke – 1991 Vol 22-P. 983–8.339. Wozakowska-Kapłon B. B-type natriuretic peptide level after sinusrhythm restoration in patients with persistent atrial fibrillation – clinical259significance.

/ Wozakowska-Kapłon B. [et al.] // Kardiol Pol. – 2010- Vol 68(7)P.781-6.340. Wyse DG. Lone atrial fibrillation: does it exist? / Wyse DG. [et al.]// J Am Coll Cardiol- 2014- Vol 63-P. 1715-1723341. Wyse DG. A comparison of rate control and rhythm control inpatients with atrial fibrillation. / Wyse DG. [et al.]//N Engl J Med.- 2002 –Vol347(23)- P.1825-33.342. Xu JZ.

Left atrial diameter, flow-mediated dilation of brachial arteryand target organ damage in Chinese patients with hypertension./ Xu JZ. [et al.] //J Hum Hypertens. -2012 -26(1)-P.41-7.343. Yahalom G. Chronic kidney disease and clinical outcome in patientswith acute stroke./ Yahalom G. [et al.]// Stroke-2009-Vol 40-P.1296-303.344. Yamashita T. J-RHYTHM II Investigators. Randomized trial ofangiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in thetreatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM IIstudy). / Yamashita T. [et al.]// Europace. – 2011- Vol 13(4)-P.473-9.345.

Yang Q. The preventive effect of atorvastatin on atrial fibrillation: ameta-analysis of randomized controlled trials./Yang Q. [et al.]// BMCCardiovasc Disord.- 2014 – Vol 13- P.14:99.346. Yang SS. Effects of spironolactone on electrical and structuralremodeling of atrium in congestive heart failure dogs./ Yang SS. [et al.]// ChinMed J.